Ignite Creation Date:
2025-12-24 @ 5:35 PM
Ignite Modification Date:
2025-12-25 @ 3:07 PM
Study NCT ID:
NCT05385068
Status:
UNKNOWN
Last Update Posted:
2022-05-23
First Post:
2022-05-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi
Sponsor:
Peking Union Medical College Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-06
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-09
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-11
First Submit QC Date:
None
Study First Post Date:
2022-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-19
Last Update Post Date:
2022-05-23
Last Update Post Date Type:
ACTUAL